Aileron Therapeutics Garners $12,000,000 Series D Financing
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=22a75b16-902c-49d4-8401-dc995286b9cf&Preview=1 -
Date
1/14/2013 -
Company Name
Aileron Therapeutics -
Mailing Address
281 Albany St. Cambridge, MA 02139 -
Company Description
Aileron Therapeutics is an emerging biopharmaceutical company that is applying its proprietary cell permeable peptide technology to generate breakthrough therapeutics
for the treatment of cancer and other diseases. Aileron’s technology is the first and
only process that allows peptides to penetrate cells in a sequence-independent manner. Aileron is developing the first generation of peptide therapeutics directed at intra-cellular protein-protein interaction targets that are not addressable by small molecule or biological drugs. -
Website
http://www.aileronrx.com -
Transaction Type
Venture Equity -
Transaction Amount
$12,000,000 -
Transaction Round
Series D -
Proceeds Purposes
Proceeds from this tranche will be directed to the clinical development of ALRN-5281 in patients with orphan endocrine disorders early this year. Initiation of the ALRN-5281 clinical trial will mark the first-ever Stapled Peptide human clinical trial. -
M&A Terms
-
Venture Investor
Apple Tree Partners -
Venture Investor
Excel Venture Management -
Venture Investor
Lilly Ventures -
Venture Investor
Novartis Venture Fund -
Venture Investor
Roche Venture Fund -
Venture Investor
SR One
